A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination With Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab/Quavonlimab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYSTEP-004
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 20 Jan 2024 Results (n-115) presented at the 2024 Gastrointestinal Cancers Symposium
- 27 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2021 Trial design presented at the 23rd World Congress on Gastrointestinal Cancer